Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Measuring Tumor Mutational Burden (TMB) in Plasma from mCRPC Patients Using Two Commercial NGS Assays

8 Jan 2019

Abstract excerpt

Tumor tissue mutational burden (TMB) has emerged as a promising predictive biomarker for immune checkpoint therapy. Measuring TMB from circulating tumor DNA (ctDNA) found in plasma is attractive in tissue-constrained indications. We compared the performance of two plasma-based commercial TMB assays including the effect of two different collection methods. Our findings suggest that the two plasma based TMB assays...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Cancer Immunotherapy and Biomarkers
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30643180
DOI: 10.1038/s41598-018-37128-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Measuring Tumor Mutational Burden (TMB) in Plasma from mCRPC Patients Using Two Commercial NGS AssaysPMID 30643180Read ↗

Utilizing Plasma Circulating Tumor DNA Sequencing for Precision Medicine in the Management of Solid Cancers.Semantic proximity Read ↗

Validity and utility of blood tumor mutational burden is dependent on circulating tumor DNA shedSemantic proximity Read ↗

Exploring real-world concordance of tissue mutation burden (TMB) from blood and tissue in patients with solid tumorsSemantic proximity Read ↗

Validity and utility of blood tumor mutational burden (bTMB) is dependent on circulating tumor DNA (ctDNA) shed: SCRUM-Japan MONSTAR-SCREENSemantic proximity Read ↗

Influence of low tumor content on tumor mutational burden estimation by whole-exome sequencing and targeted panel sequencing.Semantic proximity Read ↗

In-depth assessment of BRAF, NRAS, KRAS, EGFR, and PIK3CA mutations on cell-free DNA in the blood of melanoma patients receiving immune checkpoint inhibitionSemantic proximity Read ↗

Analysis of tumor template from multiple compartments in a blood sample provides complementary access to peripheral tumor biomarkersSemantic proximity Read ↗

Open the Technical Black Box of Tumor Mutational Burden (TMB): Factors Affecting Harmonization and Standardization of Panel-Based TMB.Semantic proximity Read ↗

Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions.Semantic proximity Read ↗

Reliability of liquid biopsy analysis: an inter-laboratory comparison of circulating tumor DNA extraction and sequencing with different platformsSemantic proximity Read ↗

Capturing tumor heterogeneity and clonal evolution in solid cancers using circulating tumor DNA analysis.Semantic proximity Read ↗

Appropriate use of cancer comprehensive genome profiling assay using circulating tumor DNA.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.